The biotech industry is undergoing a major transformation, driven by cutting-edge research, innovative treatments, and next-gen therapies. These 20 biotech startups have raised over $100M to advance their groundbreaking work in genomics, immunotherapies, and personalized medicine.
From gene editing to targeted cancer treatments and CRISPR technologies, these startups are redefining the future of healthcare.
Meet 20 Biotechnology Innovators Raising Over $100M
Explore how these biotech companies are reshaping the medical landscape with game-changing innovations and substantial funding.
Here are 20 biotechnology startups that are driving change and shaping the industry’s future!
| Company | Founded | Location | Employees | Last Funding | Last Funding Date | Total Funding |
|---|---|---|---|---|---|---|
| Colossal Biosciences | 2021 | Dallas, TX, USA | 101-250 | $200M | Jan 15, 2025 | $448.1M |
| Tenvie Therapeutics | 2025 | San Francisco, CA, USA | 11-50 | $200M | Jan 8, 2025 | $200M |
| Truveta | 2020 | Seattle, WA, USA | 101-250 | $320M | Jan 13, 2025 | $515M |
| Nuvig Therapeutics | 2021 | Redwood City, CA, USA | 11-50 | $161M | Dec 5, 2024 | $208M |
| Tune Therapeutics | 2020 | Seattle, WA, USA | 51-100 | $175M | Jan 12, 2025 | $215M |
| Kailera Therapeutics | 2024 | Waltham, MA, USA | 11-50 | $400M | Oct 1, 2024 | $400M |
| Caidya | 2021 | Morrisville, NC, USA | 1001-5000 | $165M | Jan 13, 2025 | $165M |
| Candid Therapeutics | 2024 | San Diego, CA, USA | 11-50 | $370M | Sep 9, 2024 | $370M |
| Aktis Oncology | 2021 | Boston, MA, USA | 11-50 | $175M | Sep 30, 2024 | $331M |
| Idrx | 2022 | Cambridge, MA, USA | 11-50 | $120M | Aug 7, 2024 | $242M |
| Scorpion Therapeutics | 2020 | Boston, MA, USA | 11-50 | $150M | Jul 16, 2024 | $420M |
| Shinobi Therapeutics | 2023 | South San Francisco, CA, USA | 11-50 | $68M | Aug 6, 2024 | $178M |
| Seaport Therapeutics | 2024 | Boston, MA, USA | 11-50 | $225M | Oct 21, 2024 | $325M |
| Syncromune | 2020 | Fort Lauderdale, FL, USA | 11-50 | $100M | Dec 20, 2024 | $110M |
| Treeline Biosciences | 2021 | Watertown, MA, USA | 101-250 | $421M | Oct 17, 2024 | $894.27M |
| Centessa Pharmaceuticals | 2021 | Cambridge, MA, USA | 51-100 | $225M | Sep 11, 2024 | $875M |
| CARGO Therapeutics | 2021 | San Mateo, CA, USA | 11-50 | $110M | May 28, 2024 | $310M |
| Taysha Gene Therapies | 2020 | Dallas, TX, USA | 51-100 | $75M | Jun 26, 2024 | $543M |
| Marea Therapeutics | 2022 | San Francisco, CA, USA | 1-10 | $190M | Jun 18, 2024 | $255.4M |
| Evommune | 2020 | Palo Alto, CA, USA | 11-50 | $115M | Oct 31, 2024 | $268M |
1. Colossal Biosciences
- Founded: February 4, 2021
- Location: Dallas, Texas, USA
- Industry: Biotechnology, Genetics, Life Science
- Number of Employees: 101-250
- Last Funding Amount: $200M (Latest Round: January 15, 2025)
- Total Funding Amount: $448.1M
Colossal Biosciences is a groundbreaking bioscience and genetic engineering company dedicated to restoring extinct species and safeguarding endangered ones. By utilizing advanced gene-editing technologies such as CRISPR, Colossal aims to de-extinct species like the woolly mammoth and enhance global ecosystems. The company’s innovative approach addresses the pressing issues of extinction and biodiversity loss, paving the way for the next frontier of genetic conservation. Colossal is working on transforming the field of de-extinction, with the mission to restore species that once roamed Earth and protect those on the brink of extinction.
2. Tenvie Therapeutics
- Founded: January 2025
- Location: San Francisco, California, USA
- Industry: Biotechnology, Medical, Neuroscience
- Number of Employees: 11-50
- Last Funding Amount: $200M (Latest Round: January 8, 2025)
- Total Funding Amount: $200M
Tenvie Therapeutics is a biotechnology company dedicated to improving the lives of patients suffering from neurological, cardiometabolic, and ophthalmic diseases. The company focuses on developing small molecules that target brain inflammation, metabolic dysfunction, and lysosomal issues. With a robust pipeline inherited from Denali Therapeutics, Tenvie is advancing therapeutics aimed at addressing these complex conditions.
The company’s portfolio includes fully owned, brain-penetrant, and precisely designed small molecules that target inflammation, metabolic correction, and rejuvenating lysosomal function. Tenvie is committed to transforming the treatment landscape of neurological and related diseases through engineered small molecules.
3. Truveta
- Founded: 2020
- Location: Seattle, Washington, USA
- Industry: Biotechnology, Health Care, Wellness
- Number of Employees: 101-250
- Last Funding Amount: $320M (Latest Round: January 13, 2025)
- Total Funding Amount: $515M
Truveta is a healthcare data platform that collaborates with physicians, life science researchers, and other healthcare professionals to improve patient care. By compiling medical record information from its partner organizations, Truveta connects treatments with results and various health factors, providing a rich data ecosystem to advance healthcare research. With a strong commitment to improving patient outcomes, Truveta enables researchers and healthcare providers to better understand treatments and their effects, transforming the future of healthcare through data-driven insights.
4. Nuvig Therapeutics
- Founded: 2021
- Location: Redwood City, California, USA
- Industry: Biotechnology, Health Care, Therapeutics
- Number of Employees: 11-50
- Last Funding Amount: $161M (Latest Round: December 5, 2024)
- Total Funding Amount: $208M
Nuvig Therapeutics is a biotechnology company dedicated to developing innovative therapies aimed at restoring immune homeostasis and rebalancing immune function following inflammation. The company’s goal is to improve treatment options for patients with chronic inflammatory and autoimmune diseases. Nuvig is advancing a pipeline of novel immune therapeutics that work by inducing natural mechanisms to support the immune system and mitigate disease progression. Through this approach, Nuvig aims to revolutionize the treatment of immune-related conditions and offer new hope to patients.
5. Tune Therapeutics
- Founded: 2020
- Location: Seattle, Washington, USA
- Industry: Biotechnology, Health Care, Therapeutics
- Number of Employees: 51-100
- Last Funding Amount: $175M (Latest Round: January 12, 2025)
- Total Funding Amount: $215M
Tune Therapeutics is a biotechnology company focused on developing cell and gene therapies using epigenetic programming to treat devastating diseases. The company aims to revolutionize therapeutic approaches by leveraging its epigenetic platform to program cells in a way that directly targets the underlying causes of diseases. Tune Therapeutics is advancing a range of therapies designed to address serious medical conditions, with the potential to create paradigm-shifting treatments that could change the way diseases are treated.
6. Kailera Therapeutics
- Founded: 2024
- Location: Waltham, Massachusetts, USA
- Industry: Biotechnology, Pharmaceutical, Therapeutics
- Number of Employees: 11-50
- Last Funding Amount: $400M (Latest Round: October 1, 2024)
- Total Funding Amount: $400M
Kailera Therapeutics is a clinical-stage biotechnology company focused on developing groundbreaking therapies for the treatment of obesity and related diseases. The company is advancing a range of injectable and oral GLP-1 (Glucagon-like peptide-1) therapies that aim to address the growing global health challenge of obesity. Kailera’s innovative approach seeks to improve patient outcomes by offering effective solutions to manage and treat obesity and its associated health complications.
7. Caidya
- Founded: 2021
- Location: Morrisville, North Carolina, USA
- Industry: Biotechnology, Clinical Trials, Medical
- Number of Employees: 1001-5000
- Last Funding Amount: $165M (Latest Round: January 13, 2025)
- Total Funding Amount: $165M
Caidya is a clinical research organization focused on providing personalized solutions across various therapeutic areas. The company operates and develops a proprietary technology platform that integrates data from different systems to offer a near real-time view of clinical trials. Caidya’s innovative approach aims to streamline the clinical trial process, improving efficiency and accuracy while ensuring that therapies are tailored to patient needs. With a commitment to advancing clinical research, Caidya is playing a crucial role in transforming the landscape of drug development and patient care.
8. Candid Therapeutics
- Founded: 2024
- Location: San Diego, California, USA
- Industry: Biotechnology, Product Research, Therapeutics
- Number of Employees: 11-50
- Last Funding Amount: $370M (Latest Round: September 9, 2024)
- Total Funding Amount: $370M
Candid Therapeutics is a biotechnology company dedicated to developing innovative treatments for a variety of immunological conditions. With a focus on advancing therapeutic solutions, the company aims to transform the treatment landscape for immune-related diseases. Through cutting-edge research and the development of novel therapeutics, Candid is committed to improving patient outcomes and addressing critical gaps in the current treatment options. As part of its efforts, the company is leveraging a deep understanding of immunology to bring groundbreaking therapies to market.
9. Aktis Oncology
- Founded: 2021
- Location: Boston, Massachusetts, USA
- Industry: Biotechnology, Health Care, Life Science
- Number of Employees: 11-50
- Last Funding Amount: $175M (Latest Round: September 30, 2024)
- Total Funding Amount: $331M
Aktis Oncology is a biotechnology company dedicated to pioneering a new class of targeted radiopharmaceuticals for treating a wide range of solid tumor cancers. With proprietary platforms designed to generate tumor-targeting agents optimized for alpha radiotherapy, Aktis Oncology focuses on developing molecules with high tumor penetration and extended residence time, ensuring minimal side effects and enhanced tumor elimination. The company’s innovative approach also allows clinicians to visualize and confirm target engagement before exposing the patient to therapeutic radioisotopes, offering precision in cancer treatment.
10. Idrx
- Founded: 2022
- Location: Cambridge, Massachusetts, USA
- Industry: Biotechnology, Life Science, Oncology
- Number of Employees: 11-50
- Last Funding Amount: $120M (Latest Round: August 7, 2024)
- Total Funding Amount: $242M
Idrx is a clinical-stage biopharmaceutical company that specializes in developing precision oncology therapies aimed at treating gastrointestinal stromal tumors. The company focuses on designing combination therapies that leverage engineered drug combinations to target key tumor escape mechanisms and extend the effectiveness of treatment. By targeting specific pathways involved in tumor progression, Idrx aims to improve patient outcomes and offer innovative solutions for challenging cancer types.
11. Scorpion Therapeutics
- Founded: 2020
- Location: Boston, Massachusetts, USA
- Industry: Biotechnology, Health Care, Life Science
- Number of Employees: 11-50
- Last Funding Amount: $150M (Latest Round: July 16, 2024)
- Total Funding Amount: $420M
Scorpion Therapeutics is a clinical-stage oncology company focused on precision medicine for cancer treatment. The company specializes in developing targeted small-molecule drugs designed to interact with validated cancer targets. Leveraging its proprietary platform, Scorpion aims to advance a comprehensive pipeline of fully owned, optimized compounds. This includes molecules targeting validated oncogenes, previously undruggable targets, and novel cancer-specific targets. Scorpion Therapeutics strives to offer innovative therapies that improve patient outcomes by addressing the complexities of cancer biology.
12. Shinobi Therapeutics
- Founded: 2023
- Location: South San Francisco, California, USA
- Industry: Biotechnology, Health Care, Therapeutics
- Number of Employees: 11-50
- Last Funding Amount: $68M (Latest Round: August 6, 2024)
- Total Funding Amount: $178M
Shinobi Therapeutics is a biotechnology company that develops innovative immune-evasive iPS cell therapies aimed at treating cancer and other diseases. The company focuses on creating hypoimmune CD8αβ iPS-T cells that interact with the immune system to provide more effective and accessible cell therapies. By leveraging advanced immune evasion technology, Shinobi aims to enhance the durability of responses and enable redosing capabilities, ultimately improving patient outcomes. The company is committed to reducing the costs of cell therapies while improving their overall effectiveness.
13. Seaport Therapeutics
- Founded: 2024
- Location: Boston, Massachusetts, USA
- Industry: Biotechnology, Pharmaceutical, Therapeutics
- Number of Employees: 11-50
- Last Funding Amount: $225M (Latest Round: October 21, 2024)
- Total Funding Amount: $325M
Seaport Therapeutics is a clinical-stage biopharmaceutical company committed to developing innovative therapies that target complex diseases. With a strong focus on cutting-edge therapeutics, the company aims to push the boundaries of medical science to offer transformative solutions. Seaport Therapeutics is dedicated to pioneering novel treatments, working to improve patient outcomes by addressing urgent health needs. Leveraging advanced technology and scientific expertise, the company is advancing its pipeline to provide breakthrough medicines for a wide range of medical conditions.
14. Syncromune
- Founded: 2020
- Location: Fort Lauderdale, Florida, USA
- Industry: Biotechnology, Life Science, Pharmaceutical
- Number of Employees: 11-50
- Last Funding Amount: $100M (Latest Round: December 20, 2024)
- Total Funding Amount: $110M
Syncromune™ is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for metastatic solid tumor cancers. The company is pioneering combination immunotherapies that have garnered attention from leading experts as the future of cancer treatment. Syncromune™ is advancing its proprietary platform, Syncrovax™, which creates personalized in situ vaccines using a patient’s own tumor antigens.
This unique approach optimizes immune system activation and T cell response to target and treat tumors in ways traditional therapies cannot. The company’s commitment to addressing unmet medical needs in cancer therapy positions it at the forefront of personalized treatment development for patients with difficult-to-treat conditions.
15. Treeline Biosciences
- Founded: 2021
- Location: Watertown, Massachusetts, USA
- Industry: Biotechnology, Health Care, Life Science
- Number of Employees: 101-250
- Last Funding Amount: $421M (Latest Round: October 17, 2024)
- Total Funding Amount: $894.27M
Treeline Biosciences is a biotechnology company focused on developing transformative precision medicines for patients suffering from cancer and other serious conditions. Established in 2021, the company is committed to building innovative therapies that address unmet medical needs in oncology and beyond.
Treeline Biosciences’s approach combines cutting-edge research and advanced technologies to create treatments that are tailored to individual patients, maximizing therapeutic efficacy while minimizing side effects. With a strong pipeline of precision medicines, the company aims to revolutionize cancer care and improve the lives of those with challenging health conditions.
16. Centessa Pharmaceuticals
- Founded: 2021
- Location: Cambridge, Massachusetts, USA
- Industry: Biotechnology, Pharmaceutical
- Number of Employees: 51-100
- Last Funding Amount: $225M (Latest Round: September 11, 2024)
- Total Funding Amount: $875M
Centessa Pharmaceuticals is a next-generation biopharmaceutical company dedicated to reshaping the traditional drug development process. The company utilizes an asset-centric R&D model at scale, advancing a portfolio of highly validated programs through its subsidiaries. Each program is developed by a specialized Centessa subsidiary and supported by centralized infrastructure and an experienced management team.
With a focus on innovation and efficiency, Centessa aims to expedite the development of therapies for a range of diseases, leveraging the expertise of industry-leading teams to drive progress in the biopharmaceutical space.
17. CARGO Therapeutics
- Founded: 2021
- Location: San Mateo, California, USA
- Industry: Biotechnology, Medical, Therapeutics
- Number of Employees: 11-50
- Last Funding Amount: $110M (Latest Round: May 28, 2024)
- Total Funding Amount: $310M
CARGO Therapeutics is pioneering the development of CAR T-cell therapies to overcome cancer treatment resistance and address access barriers, aiming to make potentially curative treatments available to more patients. Despite advancements in commercially available autologous CAR therapies, these treatments remain curative for less than half of cancer patients, with many unable to access them due to manufacturing, supply constraints, long turnaround times, and reimbursement barriers.
The company’s mission is to outwit cancer by developing innovative solutions to improve cancer treatment outcomes, focusing on making curative therapies more accessible and effective for a broader range of patients.
18. Taysha Gene Therapies
- Founded: January 1, 2020
- Location: Dallas, Texas, USA
- Industry: Biotechnology, Genetics, Life Science
- Number of Employees: 51-100
- Last Funding Amount: $75M (Latest Round: June 26, 2024)
- Total Funding Amount: $543M
Taysha Gene Therapies is focused on developing treatments to eradicate severe and life-threatening monogenic diseases of the central nervous system (CNS). With a singular mission to eradicate monogenic CNS diseases, the company rapidly translates innovative treatments from bench to bedside. Taysha has combined its team’s extensive expertise in gene therapy drug development with the world-class UT Southwestern Gene Therapy Program, allowing it to build a diverse AAV gene therapy pipeline. This pipeline targets both rare and large-market indications, aiming to deliver curative medicines for patients in need.
19. Marea Therapeutics
- Founded: 2022
- Location: San Francisco, California, USA
- Industry: Biotechnology, Genetics, Life Science
- Number of Employees: 1-10
- Last Funding Amount: $190M (Latest Round: June 18, 2024)
- Total Funding Amount: $255.4M
Marea Therapeutics is a clinical-stage biotechnology company that leverages the latest advancements in human genetics to develop first-in-class, next-generation therapies for cardiometabolic diseases. The company’s cutting-edge approach to drug development aims to transform the treatment landscape for these complex conditions, advancing novel therapies based on the unique insights into human genetic mechanisms. Marea is dedicated to creating innovative medications that address unmet medical needs in the cardiometabolic space.
20. Evommune
- Founded: 2020
- Location: Palo Alto, California, USA
- Industry: Biotechnology, Health Care, Life Science
- Number of Employees: 11-50
- Last Funding Amount: $115M (Latest Round: October 31, 2024)
- Total Funding Amount: $268M
Evommune is a biotechnology company that focuses on developing transformative therapies for inflammatory diseases using a tissue-based approach. The company creates novel strategies to treat inflammatory disorders by developing treatments that not only address symptoms but also halt disease progression. Evommune’s pipeline includes initiatives targeting highly prevalent inflammatory conditions, with a mission to advance real breakthroughs for patients suffering from these diseases. All of Evommune’s programs are designed to deliver best-in-class therapeutic profiles.
Conclusion
The $100M+ investment in 20 biotech startups signals an exciting future for healthcare and life sciences. These companies are pioneering groundbreaking innovations in drug development, gene therapy, diagnostics, and personalized medicine. With substantial funding, they are positioned to accelerate the pace of discovery, improve patient outcomes, and redefine the future of medical treatments.
FAQs
Q. How are these biotech startups shaping the future of healthcare?
Answer: These biotech startups are developing groundbreaking treatments for conditions like cancer, genetic disorders, and other complex diseases. By leveraging technologies like gene therapy, RNA-based therapies, and personalized medicine, they are significantly improving patient outcomes and providing more targeted treatment options.
Q. How do these biotech startups impact the global healthcare landscape?
Answer: By developing novel therapies and solutions, these startups are addressing some of the most pressing global health issues. Their work in gene therapies, cancer treatments, and personalized medicine is poised to make a lasting impact on improving health outcomes, extending life expectancy, and transforming how we approach disease treatment.
Q. What impact does AI have on biotech startups?
Answer: AI plays a crucial role in biotech by enabling faster drug discovery, predicting patient responses to treatments, and optimizing clinical trial designs. AI-driven solutions are helping these startups streamline their processes, reduce time-to-market, and improve the accuracy of their therapeutic approaches.